StockData
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. (AUPH) stock

AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3058% below fair value
$15.40−0.08 (-0.52%)

Close on Nov 17, 2026Market cap $2.06BP/E 6.7Yield –

Aurinia Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Aurinia Pharmaceuticals's pe ratio was 7.1× on Nov 11, 2026, against 28.8× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20267.1×−21.4
2025Dec 31, 202528.5×–

More Aurinia Pharmaceuticals figures

See a number that looks wrong?